NCT06450067 Inaticabtagene Autoleucel Injection Treatment for Adult Relapsed or Refractory Acute Lymphocytic Leukemia
| NCT ID | NCT06450067 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Juventas Cell Therapy Ltd. |
| Condition | B-cell Acute Lymphoblastic Leukemia |
| Study Type | OBSERVATIONAL |
| Enrollment | 200 participants |
| Start Date | 2024-06-05 |
| Primary Completion | 2026-06-05 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 200 participants in total. It began in 2024-06-05 with a primary completion date of 2026-06-05.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This clinical trial is a non-interventional, observational, multicenter, post-marketing real-world study to evaluate the efficacy and safety of Inaticabtagene Autoleucel Injection in Chinese adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia.
Eligibility Criteria
Inclusion Criteria: 1. Age ≥ 18 years; 2. Diagnosed with relapsed or refractory B-cell acute lymphoblastic leukemia; 3. Patients deemed eligible for receiving commercial Inaticabtagene Autoleucel injection treatment as determined by the investigator; 4. Patients voluntarily participate in this study and sign an informed consent form. For patients lacking full legal capacity, informed consent must be obtained from their legal guardian Exclusion Criteria: None
Contact & Investigator
Jianxiang Wang, Dr.
PRINCIPAL INVESTIGATOR
Institute of Hematology & Blood Diseases Hospital, China
Frequently Asked Questions
Who can join the NCT06450067 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying B-cell Acute Lymphoblastic Leukemia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06450067 currently recruiting?
Yes, NCT06450067 is actively recruiting participants. Contact the research team at 352074861@qq.com for enrollment information.
Where is the NCT06450067 trial being conducted?
This trial is being conducted at Beijing, China, Beijing, China, Guangzhou, China, Zhengzhou, China and 6 additional locations.
Who is sponsoring the NCT06450067 clinical trial?
NCT06450067 is sponsored by Juventas Cell Therapy Ltd.. The principal investigator is Jianxiang Wang, Dr. at Institute of Hematology & Blood Diseases Hospital, China. The trial plans to enroll 200 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.